TotalEnergies announces increased interim dividend for fiscal year 2025

Patrick Pouyanné Chairman and Chief Executive Officer TotalEnergies SE
Patrick Pouyanné Chairman and Chief Executive Officer - TotalEnergies SE
0Comments

Paris, July 24, 2025 – TotalEnergies has confirmed the distribution of a second interim dividend of €0.85 per share for the fiscal year 2025. This represents a 7.6% increase compared to the three interim dividends paid for fiscal year 2024 and matches the final ordinary dividend for that year as well as the first interim dividend for 2025. The decision was made during a Board of Directors meeting on July 23, chaired by Patrick Pouyanné, Chairman and Chief Executive Officer.

The company stated that this increase aligns with the shareholder return policy announced by its Board of Directors in February 2025.

Shareholders can expect their dividends to be paid exclusively in cash according to the following schedule: both shareholders and ADS holders will have an ex-dividend date of December 31, 2025. The payment date is set for January 5, 2026, for shareholders and January 23, 2026, for ADS holders.

TotalEnergies is a global integrated energy company involved in producing and marketing various energies including oil, biofuels, natural gas, biogas, low-carbon hydrogen, renewables, and electricity. It operates in approximately 120 countries worldwide with over 100,000 employees.

The company also provided a cautionary note about forward-looking statements contained within their announcement. They emphasized that these statements are based on economic data and assumptions considered reasonable at present but may not be accurate in the future due to various uncertainties such as economic conditions or changes in regulations.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.